Abstract
Obesity is defined as an excess of body fat. It is currently estimated that more than 1.5 billion people worldwide are overweight [1]. According to the National Health and Nutrition Examination Survey (NHANES), at least one-third of Americans are obese. Unfortunately, the tsunami of obesity led to the recent report that bariatric surgery has become the second most common abdominal operation in the USA [2]. These numbers should serve as a call to action for the implementation of obesity therapy in every primary care clinic and in most subspecialty clinics; endocrinology and diabetes care clinics are particularly important. In terms of obesity treatment, there are ample opportunities for secondary “prevention” of weight gain – in both overweight and obese patients – to keep obesity from getting worse, as well as treatment to reduce body weight and to improve health and well-being.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Haslam DW, James WP: Obesity. Lancet 2005, 366:1197–1209.
Birkmeyer NJ, Dimick JB, Share D: Hospital complication rates with bariatric surgery in Michigan. JAMA 2010, 304:435–442.
Wang S, Sparks LM, Xie H: Subtyping obesity with microarrays: implications for the diagnosis and treatment of obesity. Int J Obes (Lond) 2009, 33:481–489.
CDC: Vital signs: state-specific obesity prevalence among adults – United States, 2009. MMWR, 59:1–3.
Smith SR, Martin C, Katzmarzyk P, et al.: Obesity and diabetes: implications for management. In 2009 Educational Review Manual in Endocrinology FOCUS: Diabetes. Edited by Kendall, DM. New York: Castle Connolly Graduate Medical; 2009.
National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obes Res 1998, 6(Suppl 2):51S–209S.
Gordon-Larsen P, The NS, Adair LS: Longitudinal trends in obesity in the United States from adolescence to the third decade of life. Obesity (Silver Spring, MD) 2010, 18:1801–1804.
Prospective Studies Collaboration,Whitlock G, Lewington S, et al.: Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083–1096.
Willett WC, Manson JE, Stampfer MJ, et al.: Weight, weight change, and coronary heart disease in women. Risk within the ’normal’ weight range. JAMA 1995, 273:461–465.
Sharma AM, Padwal R: Obesity is a sign – over-eating is a symptom: an aetiological framework for the assessment and management of obesity. Obes Rev 2010, 11:362–370.
Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.
Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102–2107.
Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002, 10:633–641.
Foster GD, Wadden TA, Vogt RA, Brewer G: What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997, 65:79–85.
Sharma AM, Kushner, RF: A proposed clinical staging system for obesity. Int J Obes (Lond) 2009, 33:289–295.
Hall K: Mechanisms of metabolic fuel selection – modeling human metabolism and body weight change. IEEE Eng Med Biol Mag 2010, 29:36–41.
Catenacci VA, Ogden LG, Stuht J, et al.: Physical activity patterns in the National Weight Control Registry. Obesity (Silver Spring, MD) 2008, 16:153–161.
Butryn ML, Phelan S, Hill JO, Wing RR: Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity (Silver Spring, MD) 2007, 15:3091–3096.
Sarwer DB, von Sydow Green A, et al.: Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes 2009, 16:347–352.
West DS, DiLillo V, Bursac Z, et al.: Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care 2007, 30:1081–1087.
Heymsfield SB, van Mierlo CA, van der Knaap HC , et al.: Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003, 27:537–549.
Gupta AK, Smith SR, Greenway FL, Bray GA: Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009, 11:330–337.
Astrup A: Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010, 376:567–568.
Sjöström L, Narbro K, Sjöström CD, et al.: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741–752.
James WP, Caterson ID, Coutinho W, et al.: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363:905–917.
Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002, 346:591–602.
Munro JF, MacCuish AC, Wilson EM, Duncan LJ: Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968, 1:352–354.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161.
Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27:1437–1446.
Wadden TA, Berkowitz RI, Womble LG, et al.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353:2111–2120.
Astrup A, Toubro S: When, for whom and how to use sibutramine? Int J Obes Relat Metab Disord 2001, 25(Suppl 4):S2–S7.
Smith SR, Weissman NJ, Anderson CM, et al.: Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010, 363:245–256.
Bray GA, Hollander P, Klein S, et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11:722–733.
Smith SR, Aronne LJ, Burns CM, et al.: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31:1816–1823.
Smith SR, Blundell JE, Burns C, et al.: Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007, 293:E620–E627.
Astrup A, Rössner S, Van Gaal L, et al.: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606–1616.
Aronne LJ, Halseth AE, Burns CM, et al.: Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring, MD) 2010, 18:1739–1746.
Greenway FL, Dunayevich E, Tollefson G, et al.: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009, 94:4898–4906.
NIH conference: Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991, 115:956–961.
Thaler JP, Cummings DE: Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009, 150:2518–2525.
Buchwald H, Estok R, Fahrbach K, et al.: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248–256 e5.
Sjöström L, Gummesson A, Sjöström CD, et al.: Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009, 10:653–662.
Acknowledgments
I would like to acknowledge the two people who taught me the most about obesity therapy, Professors George Bray and Frank Greenway; Corby Martin, who introduced me to the science of behavior modification; and Tim Church, who made exercise science interesting and pertinent to obesity and diabetes.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Resources
Resources
The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Available on the NHLBI Web site at www.nhlbi.nih.gov and http://www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Smith, S.R. (2012). Obesity Therapy. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1028-7_15
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-1027-0
Online ISBN: 978-1-4614-1028-7
eBook Packages: MedicineMedicine (R0)